Global hemostasis products market is expected to reach USD 6.70 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.
The report covers forecast and analysis for the hemostasis products market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD Billion). The study includes drivers and restraints for the hemostasis products market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hemostasis products market on a global level.
In order to give the users of this report a comprehensive view on the hemostasis products market, we have to include competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product segments and application segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research& development, product and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies along with patent analysis (2011-2016) bifurcated into the patent trend, patent share by company and patent analysis according to the region.
The study provides a decisive view on the hemostasis products market by segmenting the market based on products, applications, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on products the market is segmented into topical hemostasis, infusible hemostasis, and advanced hemostasis. Key application market covered under this study includes trauma, surgery, hemophilia, myocardial infarction, stroke, and thrombosis. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for hemostasis products based on individual product and applications in all the regions and countries.
The report also includes detailed profiles of end players such as Pfizer, Inc., Medtronic plc, Abbott Laboratories, Johnson & Johnson, Integra LifeSciences Corporation, HemCon Medical Technologies, Inc., Grifols, S.A., CSL Behring LLC, C. R. Bard, Inc. and Baxter International, Inc.
This report segments the global hemostasis products market as follows:
Global Hemostasis Products Market: Product Segment Analysis
Global Hemostasis Products Market: Application Segment Analysis
Global Hemostasis Products Market: Regional Segment Analysis
This report is based on in-depth qualitative and quantitative analyses of the global Hemostasis Products market. Zion Research has collected and analyzed key data belong to the global Hemostasis Products market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Hemostasis Products across the world has been calculated through primary and secondary research.
Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Hemostasis Products industry. Primary research makes up the major source of data collection and validation.
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Hemostasis Products market.
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
Hemostasis is the process which helps to stop the bleeding from a cut or injury. Hemostasis products are designed to cease bleeding and hemorrhage caused by injuries and surgical procedures. Hemostasis involves forming a clot at the site of the damaged blood vessel and repairing the blood vessel. These products vary based on their ease of application, mechanism of action, adherence to tissue, composition, immunogenicity and cost.
The hemostasis product market is mainly driven by increasing demand supported by the rise in a number of surgery volumes. Furthermore, increasing geriatric population base coupled with rising incidences of chronic conditions are other impact hemostasis product market. According to the CDC statistics, more than 45% of the American population suffers from at least one chronic condition requiring important care. On the other hand, slow adoption of advanced hemostasis devices in emerging economies and the high cost of devices are expected to curb the market growth within the forecast period. Nevertheless, emerging market in developing countries is expected to open up new growth opportunities over the next few years.
Based on products, the hemostasis product market can be segmented into topical hemostasis, infusible hemostasis, and advanced hemostasis. The topical hemostasis are further classified into collagen, oxidized regenerated cellulose, gelatin, and polysaccharide. Infusible hemostasis includes platelet concentrates from donor blood, FVIII derived from blood, fresh frozen plasma, and prothrombin complex. In 2015, hemostasis product market dominated by topical hemostats segment. Topical hemostatis are generally used in adjunction with conventional treatment to provide minimal tissue reactivity, quick and easy absorbability of the hemostatic agent, and cost-efficiency. Moreover, infusible hemostasis and advanced hemostasis segments are anticipated to exhibit significant growth in the coming years.
The hemostasis product market can be segmented on the basis of applications such as trauma, surgery, hemophilia, myocardial infarction, stroke, and thrombosis. Surgery segment was the largest segment in 2015. Bleeding control is an important aim in surgery. Thus, this segment is expected to witness substantial growth during the forecast period. Trauma was another key outlet of this market and is anticipated to show strong growth in the years to come. More than 80% of trauma deaths that occur in the operating room do so as a result of hemorrhage. Traumatic injury is a major global health problem, accounting for approximately 1 in 10 deaths worldwide.
North America held the largest market share for hemostasis products in 2015. The dominance of the region was primarily due to increase health expenditure and technological advancement to provide innovative products. The increase in numbers of trauma cases and complex surgeries, growth geriatric population and high investment is research and development is also driving the hemostasis products market in North America. North America was followed by Asia Pacific which was another leading regional market in 2015. This growth is mainly due to increase aging population and advanced healthcare facilities. Latin America is also projected to expand at a noticeable growth rate during the forecast period.
Some of the key players operating in this market such as Pfizer, Inc., Medtronic plc, Abbott Laboratories, Johnson & Johnson, Integra LifeSciences Corporation, HemCon Medical Technologies, Inc., Grifols, S.A., CSL Behring LLC, C. R. Bard, Inc. and Baxter International, Inc.